Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Taxane and platinum chemotherapy

9 evidence topics · 11 sources

Cabazitaxel versus a second androgen receptor pathway inhibitor after docetaxel: CARD
OutcomeCabazitaxel plus prednisone or prednisolone plus G-CSFAbiraterone plus prednisone or prednisolone, or enzalutamide
Median rPFS, months (95% CI)“8.0 (5.7 to 9.2)”“3.7 (2.8 to 5.1)”
rPFS hazard ratio (95% CI)“0.54 (0.40 to 0.73)”Not applicable
Median OS, months (95% CI)“13.6 [11.5; 17.5]”“11.0 [9.2; 12.9]”
OS hazard ratio (95% CI)“0.64 [0.46; 0.89]”Not applicable